The molecule everything depends on.
NAD+ (nicotinamide adenine dinucleotide) is required for the function of sirtuins — proteins that regulate gene expression, DNA repair, and cellular stress responses, and are among the most studied targets in longevity research. It's also central to the mitochondrial processes that produce ATP, the energy currency of every cell.
NAD+ levels decline by roughly 50% between age 40 and 60. This decline is associated with decreased cellular energy production, impaired DNA repair, and reduced activity of the sirtuin proteins that protect against aging-related cellular dysfunction.
The relationship between NAD+ and aging has generated enormous research interest in the last decade. While oral NAD+ precursors (like NMN and NR) are widely available, their bioavailability through the digestive tract is limited. IV and subcutaneous delivery bypasses this limitation and produces measurably higher tissue levels.
For anyone taking longevity seriously.
NAD+ is relevant across a wide range of patient profiles. The most common are patients pursuing longevity and anti-aging protocols who want to address cellular health at a fundamental level. But it's also used for energy and cognitive performance, recovery from illness or chronic fatigue, and as part of metabolic health protocols.
NAD+ IV therapy has also been used in addiction recovery settings, where its role in neurological repair and dopamine system function has been studied.
- Cellular energy and mitochondrial function
- DNA repair and sirtuin activation
- Cognitive clarity and focus
- Recovery from illness or burnout
- Metabolic health support
- Longevity protocols
IV or subcutaneous: two approaches.
IV NAD+ delivers the highest plasma concentrations fastest, but the infusion experience can be uncomfortable — many patients experience transient chest tightness, nausea, or muscle cramping at higher infusion rates. We manage this by controlling the drip rate carefully. A typical IV session runs 2–4 hours.
Subcutaneous NAD+ is more comfortable and can be self-administered after instruction. It produces lower peak concentrations but more sustained levels. For maintenance protocols, most patients prefer this route.
Initial protocols typically involve a loading phase of several IV sessions close together, followed by maintenance via subcutaneous injection or periodic IV boosters depending on the patient's goals and response.
| Method | Duration | Experience | Best For |
|---|---|---|---|
| IV Infusion | 2–4 hours | Requires monitoring | Loading phase, acute boost |
| Subcutaneous | Minutes | Self-administered | Maintenance protocols |
| Oral (NMN/NR) | N/A | Pill | Lower bioavailability alternative |
What you should know
IV NAD+ is the one protocol where we want patients prepared for a real infusion experience. Chest tightness, nausea, muscle cramping, a feeling of pressure or flushing, and general discomfort are commonly reported during infusion. These are not signs of danger — they're a response to the rate of delivery. We manage this by slowing the drip, and most patients tolerate the infusion well once they know what to expect.
Subcutaneous NAD+ is significantly better tolerated. Mild injection site reactions are the most common complaint.
Systemically, NAD+ is a naturally occurring molecule in the body. There are no significant known long-term safety concerns.
Common questions about NAD+
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors — your body converts them into NAD+. IV and subcutaneous NAD+ delivers the molecule directly, bypassing the conversion step and achieving higher tissue concentrations. Both have value; they're different tools.
Most patients do experience sensations during the infusion — tightness, warmth, some nausea. This is normal and manageable. We control the rate carefully. First-time patients are often surprised it's not worse than expected once they understand what's happening.
After an initial loading phase, many patients maintain with monthly or quarterly IV sessions, or more frequent subcutaneous injections. The ideal frequency depends on your goals and how you respond to treatment.
Yes — NAD+ and its precursors are among the most studied molecules in the longevity space. Research into sirtuins, PARP enzymes, and mitochondrial function is robust and ongoing. Human clinical trials are more limited than preclinical data, but the mechanistic basis is well-established.
We review your labs, goals, and health history before recommending any protocol. Available in-person in St. Louis or via secure telehealth.
📅 Request a Consultation →